Want to see HK:1244 full AI Analyst Report?
1244 Stock Chart & Stats
HK$6.14
-HK$0.10(-2.80%)
At close: 4:00 PM EST
HK$6.14
-HK$0.10(-2.80%)
Day’s Range― - ―
52-Week RangeHK$1.82 - HK$10.02
Previous CloseN/A
Volume120.00K
Average Volume (3M)320.25K
Market Cap
HK$633.82M
Enterprise ValueHK$301.14
Total Cash (Recent Filing)HK$438.10M
Total Debt (Recent Filing)HK$152.85M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding258,177,000
10 Day Avg. Volume202,750
30 Day Avg. Volume320,250
Financial Highlights & Ratios
PEG Ratio1.66
Price to Book (P/B)1.97
Price to Sales (P/S)3.30
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated Oncology PlatformAn integrated oncology platform gives 3D Medicines exposure across the full product lifecycle, from discovery through commercialization. This can support greater control over development and launch execution, while approved products provide a foundation for building a broader portfolio over the next several quarters.
Very High Gross MarginA gross margin near 92% indicates that products retain substantial economic value after direct costs. If revenue stabilizes and operating expenses become better aligned with the business scale, this margin structure could provide meaningful operating leverage and support future profitability improvement.
Manageable LeverageModerate and declining debt-to-equity suggests the company is not currently heavily debt-funded, reducing balance-sheet pressure relative to a more leveraged business. This provides some financial flexibility while management works to improve operations, although ongoing losses still require careful capital management.
Bears Say
Contracting RevenueMulti-year revenue contraction indicates pressure on commercial performance and reduces operating leverage across the business. Unless the company restores topline growth through its oncology portfolio, declining sales can make it harder to absorb fixed research, development, and commercialization costs.
Persistent Large LossesNarrowing losses are encouraging, but the company remains materially unprofitable, with both operating and net margins deeply negative. Continued losses limit internally generated capital, increase dependence on successful product execution, and make sustained bottom-line profitability an unresolved fundamental challenge.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is still consuming cash to fund operations rather than self-financing growth. If the burn continues, reliance on external financing may increase, while the associated cash needs can constrain investment and reduce resilience.
3D Medicines, Inc. News
1244 FAQ
What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$1.82 and its highest was HK$10.02 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$633.82M.
When is 3D Medicines, Inc.’s upcoming earnings report date?
3D Medicines, Inc.’s upcoming earnings report date is Apr 01, 2027 which is in 205 days.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Aug 31, 2026. The company reported -HK$0.395 earnings per share for the quarter.
Is 3D Medicines, Inc. overvalued?
According to Wall Street analysts 3D Medicines, Inc.’s price is currently Overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.395 in its last earnings report. Following the earnings report the stock price went down -4.432%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3D Medicines, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
3D Medicines, Inc.
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Technical Analysis
Alphamab Oncology
―
JW (Cayman) Therapeutics Co. Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―